Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taiyo to Announce New Business Strategy around October
June 13, 2011
- Torii: Double-digit Decreases in Profits
June 13, 2011
- CHMP Recommends Approval for Astellas' Antibiotic Vibativ
June 13, 2011
- 9 Companies Inaugurate Japan CSO Association on June 1
June 13, 2011
- Nippon Chemiphar: Sales Up 14% Driven by Generics
June 13, 2011
- PMDA Proposes Fees for Regulatory Strategy Consultation Services
June 13, 2011
- FDA Approves GE Versions of Aricept from 15 Companies
June 13, 2011
- Seikagaku: Net profits Down 31.4% due to Impact of Disaster
June 13, 2011
- METI to Relax Power Use Restriction for Drug-related Companies
June 13, 2011
- JAMS, PSJ to Directly Exchange Opinions on Switch OTC Drug Candidates
June 13, 2011
- JCR: EPO Biosimilar Props Up Business
June 13, 2011
- Patent Office to Resume Discussions on Patent Extension for DDS Formulations
June 13, 2011
- Korosho Approves Kowa's Menstrual Pain Relieving Agents as Class 1 OTC Drug
June 13, 2011
- Wholesalers Were the Only Losers: Chairman Matsutani of Toho
June 6, 2011
- Eisai, UCL to Collaborate in Neurodegenerative Disease
June 6, 2011
- ASKA Licenses Ulipristal from Laboratoire HRA
June 6, 2011
- Nihon Chouzai to Open More Stores Filling Prescriptions from Wide Range of Med Institutions
June 6, 2011
- Pfizer Japan Signs Comprehensive Agreement with NCC for Clinical Trials of Anticancer Drugs
June 6, 2011
- Kantar Health Highlights Crizotinib
June 6, 2011
- R&I Downgrades Takeda Following Announcement of Acquisition of Nycomed
June 6, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…